Crenolanib

Unknown Manufacturer

Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.

Generate AI report

Overview

Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.

Technical identifiers

Chemical Formula: C₂₆H₂₉N₅O₂
CAS Number: 670220-88-9
UNII ID: LQF7I567TQ

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Crenolanib for treating FLT3 mutated proliferative disorders
US 9101624 B2Applicant: AROG PHARMACEUTICALS LLCPriority: 2013
CN
US
10 publications
CRYSTAL FORMS OF CRENOLANIB AND METHODS OF USE THEREOF
EP 4181923 A4Applicant: AROG PHARMACEUTICALS INCPriority: 2020
CN
EP
US
WO
9 publications
Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
- US 11078541 B2
  Applicant: AROG PHARMACEUTICALS INCPriority: 2016
  CN
  US
  4 publications
- US 12534764 B2
  Applicant: AROG PHARMACEUTICALS INCPriority: 2021
  US
- US 12662706 B2
  Applicant: AROG PHARMACEUTICALS INCPriority: 2022
  US
Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment
US 11857546 B2Applicant: AROG PHARMACEUTICALS INCPriority: 2022
US
3 publications
Crenolanib combination therapy
US 11602533 B2Applicant: AROG PHARMACEUTICALS INCPriority: 2018
CN
US
2 publications
Uses of crenolanib
US 11471451 B2Applicant: AROG PHARMACEUTICALS INCPriority: 2019
CN
US
2 publications
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
- US 12383549 B2
  Applicant: AROG PHARMACEUTICALS INCPriority: 2024
  US
  2 publications
- US 11969420 B2
  Applicant: AROG PHARMACEUTICALS INCPriority: 2021
  US
Preparation method of anticancer drug
CN 109678849 AApplicant: BEIJING YUEKANG KECHUANG MEDICINE TECH CO LTDPriority: 2019
CN
含高三尖杉酯碱的药物组合物及其应用
CN 112704679 BApplicant: 沈阳药科大学Priority: 2019
CN
三氧化二砷与FLT3抑制剂的药物组合物及其应用
CN 110935027 BApplicant: 沈阳药科大学Priority: 2019
CN

Drugs

Crenolanib

Overview

Patents

Crenolanib for treating FLT3 mutated proliferative disorders associated mutations

Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders